Adrian Grenier Named Chief Earth Advocate for World View
31.3.2022 18:00:00 EEST | Business Wire | Press release
World View, the leading stratospheric ballooning and space tourism company, today announced environmentalist, actor, and UN Environment Goodwill Ambassador Adrian Grenier has been named its Chief Earth Advocate. In this new role he will support World View’s mission to rediscover Earth, inspiring new perspectives on the planet and encouraging deeper respect for it as a living organism. Today’s announcement follows the company’s entry into the space tourism and exploration market offering an affordable, long duration and accessible space experience on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005341/en/
Adrian Grenier, World View Chief Earth Advocate (Photo credit: Courtesy of World View)
World View designed its space tourism experience based on the company’s business purpose: World View exists to inspire, create, and explore new perspectives for a radically improved future. The company believes its space tourism experience provides customers with an “awe inspiring” journey, from the time spent at one of World View’s spaceports to the time spent at the edge of space. World View is on a mission to deliver this transformative moment to a critical mass of humans knowing that it could lead to a markedly improved future for our fragile planet.
In his new role, Grenier will collaborate with World View’s leadership to ideate and develop strategies to ensure the company's sustainability goals are met through global partnerships, programming, and initiatives. He will also contribute to the development of its environmental strategy while playing a key role in helping participants understand their individual relationship to the planet as they prepare for and reflect on their trip.
"Adrian’s history as an eco-activist speaks for itself. World View is happy to welcome Adrian as our Chief Earth Advocate. Our main goal is to enable customers to see the beauty of the Earth we inhabit so we can radically improve the future of our own planet. Adrian is an excellent advocate and will help us in our mission,” said Ryan Hartman, President and CEO of World View.
Conservation has long been at the heart of Grenier’s social activism. In 2017, he helped the UN Environment Programme launch Clean Seas, a campaign to end marine plastic pollution. He also supported Wild for Life, advocating for the conservation of sawfish. The Lonely Whale Foundation, which he co-founded, strives to inspire empathy towards marine species and develop lifelong advocates for ocean health. Its innovative StopSucking campaign aims to discourage the use of single-use plastic straws, which are particularly harmful to marine wildlife. Grenier actively supports organizations focused on habit-changing education.
“I am honored to serve as World View’s Chief Earth Advocate. The partnership allows me to use my platform to champion healthier, regenerative choices for the Earth. Space tourism is an exciting concept, and the fact that World View puts our interconnectedness squarely at the heart of exploration is in line with my personal values. Together, we will be able to honor the planet and encourage future generations to be better stewards of its resources and beauty,” said Adrian Grenier, Chief Earth Advocate of World View.
World View Mission: Rediscover Earth
World View’s global space tourism program will begin its first commercial flights in early 2024. Unlike any other space tourism company, World View plans to have flights depart from state-of-the-art spaceports located in iconic locations like the Grand Canyon and Great Barrier Reef, providing participants the opportunity to experience natural and man-made wonders from the ground and the edge of space.
Flights will lift eight participants and two World View crew members in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles into the stratosphere, for a life-changing experience that will last six to 12 hours with average flight duration between six and eight hours. Participants will lift off before dawn to watch the sunrise over Earth, view the curvature of our planet and experience the darkness of space. They will see a world without borders, without race and will fully experience and immerse themselves in the beauty, fragility, history, and importance of the areas surrounding each location and of the Earth itself.
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005341/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
